Allergic bronchopulmonary Aspergillosis in children.

Autor: Atay Ö; Department of Pediatric Immunology and Allergy, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey., Asilsoy S; Department of Pediatric Immunology and Allergy, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey., Atakul G; Department of Pediatric Immunology and Allergy, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey., Al S; Department of Pediatric Immunology and Allergy, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey., Boyacıoğlu ÖK; Division of Nephrology, Department of Internal Medicine, Mersin State Hospital, Mersin, Turkey., Uzuner N; Department of Pediatric Immunology and Allergy, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey., Karaman Ö; Department of Pediatric Immunology and Allergy, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey.
Jazyk: angličtina
Zdroj: Turkish journal of medical sciences [Turk J Med Sci] 2021 Oct; Vol. 51 (5), pp. 2554-2563. Date of Electronic Publication: 2021 Jun 24.
DOI: 10.3906/sag-2104-227
Abstrakt: Background: Allergic bronchopulmonary aspergillus (ABPA) is a lung disease caused by hypersensitivity from Aspergillus fumigatus. Diagnostic criteria, staging systems and treatment methods for ABPA disease have been reported in studies evaluating populations, the majority of which are adult patients. Our study aimed to discuss the use of ABPA diagnostic criteria in children, the success of other alternative regimens to oral corticosteroids in the treatment of ABPA, and the changes that occur during treatment, in the light of the literature.
Methods: Between January 2017 and 2020, patients diagnosed with ABPA at the Dokuz Eylül University Child Allergy and Immunology clinic were identified; demographic characteristics, clinical and laboratory findings, diagnostic scores and stages, and treatment protocols were analyzed retrospectively.
Results: The mean age of patients diagnosed with ABPA was 14.33 ± 1.96. At the time of ABPA diagnosis, the median total IgE level was 1033 IU/mL (1004-6129), and the median AF specific IgE was 10.64 (2.59-49.70) kU/L. Bronchiectasis was detected in HRCT of 5 cases. We detected significant improvement in spirometric analysis with omalizumab treatment in our patient with steroid-related complications.
Discussion: Today, although risk factors have been investigated for ABPA, it has not been revealed clearly. Both diagnostic criteria and treatment regimens have been described in research studies, mostly adults. In pediatric patients; clarification of diagnosis and treatment algorithms is necessary to prevent irreversible lung tissue damage and possible drug side effects.
Databáze: MEDLINE
Externí odkaz: